BioCentury | Aug 8, 2018
Politics & Policy

Rep. Collins indicted with insider trading in biotech shares

...jury charged Rep. Christopher Collins (R-N.Y.) Wednesday with insider trading in shares of Australian biotech Innate Immunotherapeutics...
...Ltd. (Melbourne, Australia), when it gained two preclinical cancer candidates targeting focal adhesion kinase (FAK). Mary Romeo MIS416 Innate Immunotherapeutics...
BioCentury | Jul 7, 2017
Clinical News

Innate's MIS416 fails in Phase IIb for MS

...of caspase recruitment domain family member 15 (NOD2; CARD15) and toll-like receptor 9 (TLR9) ligands. Innate Immunotherapeutics...
...BPI), neurodegeneration as measured by MRI and immune biomarkers Status: Phase IIb data Milestone: NA Alicia Parker MIS416 Innate Immunotherapeutics...
BioCentury | Feb 1, 2017
Politics & Policy

Dems delaying Price confirmation

...Brown cited a report that Price received a "privileged offer" to purchase discounted shares of Innate Immunotherapeutics...
BioCentury | Jan 25, 2017
Politics & Policy

Price unenthusiastic about Medicare drug negotiations

...other Democrats pounded Price over allegations that he under-reported the value of his investments in Innate Immunotherapeutics...
BioCentury | Jan 19, 2017
Politics & Policy

Price bobs and weaves on drug prices

...criticized were made by a stock broker without Price’s prior knowledge. Price acknowledged investing in Innate Immunotherapeutics...
BioCentury | Oct 20, 2014
Product Development

Walking the toll road

...public financings, including three IPOs in 2014: VBL Therapeutics Ltd. , Immune Design Corp. and Innate Immunotherapeutics...
...LSE:GSK; NYSE:GSK), London, U.K. Idera Pharmaceuticals Inc. (NASDAQ:IDRA),Cambridge, Mass. Immune Design Corp. (NASDAQ:IMDZ), Seattle, Wash. Innate Immunotherapeutics...
...Ph III BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) BL-7040 TLR9 Inflammatory bowel disease (IBD) Ph II Innate Immunotherapeutics...
BioCentury | Jan 6, 2014
Finance

2014 Financial Markets Preview: Hoping the pause is brief

...12/25/13 $28.5 $242.4 $265.9 9% Human Metabolome Technologies Inc. (Tokyo:6090) 12/24/13 $11.4 $63.6 $244.3 284% Innate Immunotherapeutics...
BioCentury | Dec 23, 2013
Financial News

Innate Immunotherapeutics completes IPO

Innate Immunotherapeutics Ltd. (ASX:IIL), Auckland, New Zealand Business: Autoimmune, Cancer, Infectious Date completed: 12/17/13 Type: IPO Raised: A$10 million ($9 million) Shares: 50 million Price: A$0.20 Shares after offering: 172.6 million Underwriters: Patersons Securities; Morgans...
BioCentury | Dec 19, 2013
Financial News

Innate raises $9 million in Australian IPO

Innate Immunotherapeutics Ltd. (Auckland, New Zealand) raised A$10 million ($9 million) through the sale of 50 million shares at A$0.20 in an IPO on the Australian Stock Exchange. The price values Innate at A$34.5 million...
BioCentury | Dec 9, 2013
Financial News

Innate Immunotherapeutics proposes IPO

...to A$12 million ($11 million) Shares: 60 million Price: A$0.20 Underwriters: Patersons Securities; Morgans Note: Innate Immunotherapeutics...
Items per page:
1 - 10 of 13
BioCentury | Aug 8, 2018
Politics & Policy

Rep. Collins indicted with insider trading in biotech shares

...jury charged Rep. Christopher Collins (R-N.Y.) Wednesday with insider trading in shares of Australian biotech Innate Immunotherapeutics...
...Ltd. (Melbourne, Australia), when it gained two preclinical cancer candidates targeting focal adhesion kinase (FAK). Mary Romeo MIS416 Innate Immunotherapeutics...
BioCentury | Jul 7, 2017
Clinical News

Innate's MIS416 fails in Phase IIb for MS

...of caspase recruitment domain family member 15 (NOD2; CARD15) and toll-like receptor 9 (TLR9) ligands. Innate Immunotherapeutics...
...BPI), neurodegeneration as measured by MRI and immune biomarkers Status: Phase IIb data Milestone: NA Alicia Parker MIS416 Innate Immunotherapeutics...
BioCentury | Feb 1, 2017
Politics & Policy

Dems delaying Price confirmation

...Brown cited a report that Price received a "privileged offer" to purchase discounted shares of Innate Immunotherapeutics...
BioCentury | Jan 25, 2017
Politics & Policy

Price unenthusiastic about Medicare drug negotiations

...other Democrats pounded Price over allegations that he under-reported the value of his investments in Innate Immunotherapeutics...
BioCentury | Jan 19, 2017
Politics & Policy

Price bobs and weaves on drug prices

...criticized were made by a stock broker without Price’s prior knowledge. Price acknowledged investing in Innate Immunotherapeutics...
BioCentury | Oct 20, 2014
Product Development

Walking the toll road

...public financings, including three IPOs in 2014: VBL Therapeutics Ltd. , Immune Design Corp. and Innate Immunotherapeutics...
...LSE:GSK; NYSE:GSK), London, U.K. Idera Pharmaceuticals Inc. (NASDAQ:IDRA),Cambridge, Mass. Immune Design Corp. (NASDAQ:IMDZ), Seattle, Wash. Innate Immunotherapeutics...
...Ph III BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) BL-7040 TLR9 Inflammatory bowel disease (IBD) Ph II Innate Immunotherapeutics...
BioCentury | Jan 6, 2014
Finance

2014 Financial Markets Preview: Hoping the pause is brief

...12/25/13 $28.5 $242.4 $265.9 9% Human Metabolome Technologies Inc. (Tokyo:6090) 12/24/13 $11.4 $63.6 $244.3 284% Innate Immunotherapeutics...
BioCentury | Dec 23, 2013
Financial News

Innate Immunotherapeutics completes IPO

Innate Immunotherapeutics Ltd. (ASX:IIL), Auckland, New Zealand Business: Autoimmune, Cancer, Infectious Date completed: 12/17/13 Type: IPO Raised: A$10 million ($9 million) Shares: 50 million Price: A$0.20 Shares after offering: 172.6 million Underwriters: Patersons Securities; Morgans...
BioCentury | Dec 19, 2013
Financial News

Innate raises $9 million in Australian IPO

Innate Immunotherapeutics Ltd. (Auckland, New Zealand) raised A$10 million ($9 million) through the sale of 50 million shares at A$0.20 in an IPO on the Australian Stock Exchange. The price values Innate at A$34.5 million...
BioCentury | Dec 9, 2013
Financial News

Innate Immunotherapeutics proposes IPO

...to A$12 million ($11 million) Shares: 60 million Price: A$0.20 Underwriters: Patersons Securities; Morgans Note: Innate Immunotherapeutics...
Items per page:
1 - 10 of 13